$LGIQ
Logiq Inc

2023 Q2 Form 10-K Financial Statement

#000157587223000678 Filed on May 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q4 2022
Revenue $4.861M $8.556M $25.71M
YoY Change -1.81% -34.87% -31.15%
Cost Of Revenue $4.331M $7.953M $19.78M
YoY Change 38.34% -12.22% -24.78%
Gross Profit $529.9K $603.3K $5.935M
YoY Change -70.88% -85.2% -46.32%
Gross Profit Margin 10.9% 7.05% 23.08%
Selling, General & Admin $3.629M $623.8K $18.39M
YoY Change -41.57% -87.44% -10.11%
% of Gross Profit 684.76% 103.4% 309.9%
Research & Development $0.00 $3.387M $6.004M
YoY Change -100.0% -0.1% -18.87%
% of Gross Profit 0.0% 561.41% 101.16%
Depreciation & Amortization $420.6K $7.913M $68.54K
YoY Change 3499.52% 667.58% -98.19%
% of Gross Profit 79.38% 1311.61% 1.15%
Operating Expenses $4.049M $11.92M $55.09M
YoY Change -51.1% 27.0% 74.1%
Operating Profit -$3.519M -$11.32M -$49.16M
YoY Change -45.52% 113.07% 138.76%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$45.91K -$6.160K -$3.592K
YoY Change 7787.46% -133.33% -100.76%
Pretax Income -$3.565M -$31.03M -$49.16M
YoY Change -44.82% 486.01% 144.41%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.565M -$31.03M -$49.16M
YoY Change -44.82% 485.86% 144.27%
Net Earnings / Revenue -73.35% -362.62% -191.21%
Basic Earnings Per Share -$0.04 -$1.39
Diluted Earnings Per Share -$0.04 -$0.65 -$1.39
COMMON SHARES
Basic Shares Outstanding 74.40M 47.36M shares 35.28M
Diluted Shares Outstanding 89.35M 35.28M

Balance Sheet

Concept 2023 Q2 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $489.2K $472.2K $472.2K
YoY Change 23.41% -69.8% -69.8%
Cash & Equivalents $489.2K $472.2K $472.2K
Short-Term Investments
Other Short-Term Assets $282.2K $279.7K $279.7K
YoY Change -63.6% -69.56% -69.56%
Inventory
Prepaid Expenses $102.2K $41.59K
Receivables $837.5K $1.650M $1.650M
Other Receivables $483.9K $0.00 $0.00
Total Short-Term Assets $2.093M $2.402M $2.402M
YoY Change -39.88% -82.42% -82.42%
LONG-TERM ASSETS
Property, Plant & Equipment $63.42K $85.43K $85.43K
YoY Change -50.67% -44.52% -44.52%
Goodwill $5.578M $5.578M
YoY Change 0.0% 0.0%
Intangibles $6.301M $7.119M
YoY Change -50.66% -51.89%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.94M $12.78M $12.78M
YoY Change -35.36% -37.73% -37.73%
TOTAL ASSETS
Total Short-Term Assets $2.093M $2.402M $2.402M
Total Long-Term Assets $11.94M $12.78M $12.78M
Total Assets $14.04M $15.18M $15.18M
YoY Change -36.08% -55.58% -55.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.145M $5.073M $5.073M
YoY Change 69.57% 121.17% 121.17%
Accrued Expenses $2.255M $2.186M $2.186M
YoY Change 17.89% 2287.77% 15.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.399M $7.520M $7.520M
YoY Change 40.0% 63.44% 63.44%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.399M $7.520M $7.520M
Total Long-Term Liabilities $10.00K $10.00K $10.00K
Total Liabilities $5.409M $7.530M $7.530M
YoY Change 39.9% 63.3% 63.3%
SHAREHOLDERS EQUITY
Retained Earnings -$147.4M -$131.4M
YoY Change 59.05% 59.77%
Common Stock $9.585K $5.512K
YoY Change 186.98% 109.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.626M $7.654M $7.654M
YoY Change
Total Liabilities & Shareholders Equity $14.04M $15.18M $15.18M
YoY Change -36.08% -55.58% -55.58%

Cashflow Statement

Concept 2023 Q2 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$3.565M -$31.03M -$49.16M
YoY Change -44.82% 485.86% 144.27%
Depreciation, Depletion And Amortization $420.6K $7.913M $68.54K
YoY Change 3499.52% 667.58% -98.19%
Cash From Operating Activities -$3.205M -$4.747M -$15.72M
YoY Change -37.99% 6.83% -6.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $113.5K $0.00 $7.209M
YoY Change -100.0% -872.15%
Cash From Investing Activities $113.5K $0.00 $7.209M
YoY Change -100.0% -872.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.542M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.829M 4.831M 7.401M
YoY Change 56.04% 423.13% -53.41%
NET CHANGE
Cash From Operating Activities -3.205M -4.747M -15.72M
Cash From Investing Activities 113.5K 0.000 7.209M
Cash From Financing Activities 2.829M 4.831M 7.401M
Net Change In Cash -261.8K 83.93K -1.114M
YoY Change -92.2% -102.22% -41.47%
FREE CASH FLOW
Cash From Operating Activities -$3.205M -$4.747M -$15.72M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Trading Symbol
TradingSymbol
lgiq
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001335112
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Security Exchange Name
SecurityExchangeName
NONE
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
602751
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
155592
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5057897
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
230 Victoria Street Bugis Junction
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
#15-01/08
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Singapore
CY2022 dei Entity File Number
EntityFileNumber
000-51815
CY2022 dei Entity Registrant Name
EntityRegistrantName
LOGIQ, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Address Country
EntityAddressCountry
SG
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
188024
CY2022 dei City Area Code
CityAreaCode
+65
CY2022 dei Local Phone Number
LocalPhoneNumber
9366 2322
CY2022 dei Security12g Title
Security12gTitle
Common Stock, $0.0001 par value per share
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
24144000
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74397046
CY2022 dei Auditor Name
AuditorName
Centurion ZD CPA & Co.
CY2022 dei Auditor Location
AuditorLocation
Hong Kong
CY2022 dei Auditor Firm
AuditorFirmId
2769
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7119111
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14797196
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
85430
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
153973
CY2022Q4 us-gaap Goodwill
Goodwill
5577926
CY2021Q4 us-gaap Goodwill
Goodwill
5577926
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
12782467
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
20529095
CY2022Q4 lgiq Amount Due From Associate
AmountDueFromAssociate
0
CY2021Q4 lgiq Amount Due From Associate
AmountDueFromAssociate
7208700
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1649632
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3966086
CY2022Q4 lgiq Right To Use Assets Operating Leases
RightToUseAssetsOperatingLeases
58122
CY2021Q4 lgiq Right To Use Assets Operating Leases
RightToUseAssetsOperatingLeases
91571
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
221591
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
804011
CY2022Q4 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
0
CY2021Q4 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
681
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
22513
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
472206
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1563752
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2401551
CY2021Q4 us-gaap Assets Current
AssetsCurrent
13657314
CY2022Q4 us-gaap Assets
Assets
15184018
CY2021Q4 us-gaap Assets
Assets
34186409
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5073315
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2293858
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
2169893
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1804131
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10500
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16589
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
91571
CY2022Q4 us-gaap Deposit Liability Current
DepositLiabilityCurrent
260220
CY2021Q4 us-gaap Deposit Liability Current
DepositLiabilityCurrent
401028
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7520017
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4601088
CY2022Q4 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
10000
CY2021Q4 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
10000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
10000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
10000
CY2022Q4 us-gaap Liabilities
Liabilities
7530017
CY2021Q4 us-gaap Liabilities
Liabilities
4611088
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55118520
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55118520
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26350756
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26350756
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5512
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2635
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94829417
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
82473004
CY2022Q4 lgiq Capital Reserves
CapitalReserves
44232194
CY2021Q4 lgiq Capital Reserves
CapitalReserves
29349795
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131413122
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82250113
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7654001
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
29575321
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15184018
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34186409
CY2022 us-gaap Revenues
Revenues
25711991
CY2021 us-gaap Revenues
Revenues
37346859
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
19776533
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
26290203
CY2022 lgiq Gross Income
GrossIncome
5935458
CY2021 lgiq Gross Income
GrossIncome
11056656
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
10996628
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3782136
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17158766
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18166721
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1235233
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2296483
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
19700000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6004248
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7400732
CY2022 us-gaap Operating Expenses
OperatingExpenses
55094875
CY2021 us-gaap Operating Expenses
OperatingExpenses
31646072
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-49159417
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-20589416
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3592
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
474510
CY2022 us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-49163009
CY2021 us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-20114906
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
11881
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-49163009
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20126787
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.3936
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.3936
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.9499
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9499
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35277343
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35277343
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21187556
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21187556
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-49163009
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20126787
CY2022 us-gaap Depreciation
Depreciation
68543
CY2021 us-gaap Depreciation
Depreciation
52824
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10928085
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3729313
CY2022 us-gaap Increase Decrease In Securities Loaned Transactions
IncreaseDecreaseInSecuritiesLoanedTransactions
0
CY2021 us-gaap Increase Decrease In Securities Loaned Transactions
IncreaseDecreaseInSecuritiesLoanedTransactions
-507068
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2316454
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1347592
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3250000
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-582420
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
597569
CY2022 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
2779457
CY2021 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
1284654
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
365762
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
693399
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-41533
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
CY2022 lgiq Increase Decrease In Impairment Loss
IncreaseDecreaseInImpairmentLoss
-19700000
CY2021 lgiq Increase Decrease In Impairment Loss
IncreaseDecreaseInImpairmentLoss
0
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-10500
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-36357
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15724321
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16855183
CY2022 lgiq Increase Decrease In Amount Due From Associate
IncreaseDecreaseInAmountDueFromAssociate
-7208700
CY2021 lgiq Increase Decrease In Amount Due From Associate
IncreaseDecreaseInAmountDueFromAssociate
1535000
CY2022 lgiq Payments To Acquire Financial Assets Held For Resale
PaymentsToAcquireFinancialAssetsHeldForResale
-681
CY2021 lgiq Payments To Acquire Financial Assets Held For Resale
PaymentsToAcquireFinancialAssetsHeldForResale
-593582
CY2022 lgiq Net Restricted Cash Acquired In Acquisition Fixel
NetRestrictedCashAcquiredInAcquisitionFixel
0
CY2021 lgiq Net Restricted Cash Acquired In Acquisition Fixel
NetRestrictedCashAcquiredInAcquisitionFixel
7736
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7209381
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-933682
CY2022 lgiq Proceeds From Shares To Be Issueds
ProceedsFromSharesToBeIssueds
-140808
CY2021 lgiq Proceeds From Shares To Be Issueds
ProceedsFromSharesToBeIssueds
401028
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7541689
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11573540
CY2022 lgiq Proceeds From Stock Issuance From Ipo Net Of Expenses
ProceedsFromStockIssuanceFromIPONetOfExpenses
0
CY2021 lgiq Proceeds From Stock Issuance From Ipo Net Of Expenses
ProceedsFromStockIssuanceFromIPONetOfExpenses
3910784
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7400881
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15885352
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1114059
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1903513
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1586265
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3489778
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
472206
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1586265
CY2022 lgiq Issuance Of Shares For Services Received
IssuanceOfSharesForServicesReceived
10840852
CY2021 lgiq Issuance Of Shares For Services Received
IssuanceOfSharesForServicesReceived
3534545
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
23903508
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9287852
CY2021 lgiq Stock Issued During Period For Value Acquisitions
StockIssuedDuringPeriodForValueAcquisitions
10064515
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-9
CY2021 lgiq Stock Issued During Period Issuance Of Shares For Services
StockIssuedDuringPeriodIssuanceOfSharesForServices
3535056
CY2021 lgiq Cancellation Of Shares For Convertible Note
CancellationOfSharesForConvertibleNote
2911186
CY2021 us-gaap Profit Loss
ProfitLoss
-20126787
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
29575321
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27241702
CY2022 lgiq Cancellation Of Shares For Proceeds
CancellationOfSharesForProceeds
-13
CY2022 us-gaap Profit Loss
ProfitLoss
-49163009
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7654001
CY2021Q4 lgiq App Logiq Spinoff Description
AppLogiqSpinoffDescription
GoLogiq is a fully reporting U.S. public company. In connection with the Separation, the Company announced that it intended to distribute, on a pro rata basis, 100%
CY2022Q4 us-gaap Trade Receivables Held For Sale Amount
TradeReceivablesHeldForSaleAmount
1649632
CY2022Q1 lgiq App Logiq Spinoff Description
AppLogiqSpinoffDescription
The Company held the GoLogiq Shares until it distributed 100% of the GoLogiq Shares to the Company’s stockholders of record as of December 30, 2021 on a 1-for-1 basis (i.e. for every 1 share of Logiq held on December 30, 2021, the holder thereof will receive 1 share of Lovarra)
CY2022 lgiq Data Logiq Spinoff Description
DataLogiqSpinoffDescription
At Closing Abri will deliver to the Company $114 million worth of shares Abri common stock, par value $0.0001, at $10.00 per share (the “Merger Consideration Shares”). Also at Closing, the Company will issue a dividend to its shareholders on a pro-rata basis equal to 25% of the aggregate Merger Consideration Shares (the “Dividend Shares”), payable to the Company shareholders of record as of a record date to be set shortly before Closing.
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin: 0px 0px 0px 0in; text-align: justify; line-height: 12pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">USE OF ESTIMATES</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; line-height: 12pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; line-height: 12pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company’s financial statements in conformity with generally accepted accounting principles of the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management makes its best estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Actual results could differ from those estimates.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; line-height: 12pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div>
CY2022 lgiq Operating Segments
OperatingSegments
0.10
CY2022Q4 us-gaap Retail Land Sales Receivables Stated Interest Rate
RetailLandSalesReceivablesStatedInterestRate
1
CY2022 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P5Y
CY2022 us-gaap Amortization Of Acquisition Costs
AmortizationOfAcquisitionCosts
10928085
CY2021 us-gaap Amortization Of Acquisition Costs
AmortizationOfAcquisitionCosts
3729313
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin: 0px 0px 0px 0in; text-align: justify; line-height: 12pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ACCOUNTS RECEIVABLE AND CONCENTRATION OF RISK</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; line-height: 12pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; line-height: 12pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable consists of trade receivables from customers. The Company records accounts receivable at its net realizable value, recognizing an allowance for doubtful accounts based on our best estimate of probable credit losses on our existing accounts receivable. Balances are written off against the allowance after all means of collection have been exhausted and the possibility of recovery is considered remote.</div></div>
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
21603721
CY2022 lgiq Additions On Intangible Assets
AdditionsOnIntangibleAssets
3250000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24853721
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6806525
CY2022 lgiq Charge For Period For Intangible Assets
ChargeForPeriodForIntangibleAssets
10928085
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17734610
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7119111
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14797196
CY2022 lgiq Amortization Of Intangible Assets Net
AmortizationOfIntangibleAssetsNet
10928085
CY2021 lgiq Amortization Of Intangible Assets Net
AmortizationOfIntangibleAssetsNet
3729313
CY2021 lgiq Accounts Receivable Provision For Bad Debts
AccountsReceivableProvisionForBadDebts
100973
CY2022 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2021 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1288111
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1288111
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1276511
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
1162978
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
2103400
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7119111
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
253362
CY2022 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
0
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
253362
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
99389
CY2022 lgiq Charge For Period
ChargeForPeriod
68543
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
167932
CY2022Q4 lgiq Net Property And Equipments
NetPropertyAndEquipments
85430
CY2021Q4 lgiq Net Property And Equipment
NetPropertyAndEquipment
153973
CY2022 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
68543
CY2021 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
52824
CY2022Q4 us-gaap Goodwill Gross
GoodwillGross
5577926
CY2021Q4 us-gaap Goodwill Gross
GoodwillGross
5577926
CY2022Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2021Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2022Q4 us-gaap Goodwill
Goodwill
5577926
CY2021Q4 us-gaap Goodwill
Goodwill
5577926
CY2022Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
2252383
CY2021Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
4121678
CY2022 lgiq Allowance For Doubtful Debts
AllowanceForDoubtfulDebts
-602751
CY2021 lgiq Allowance For Doubtful Debts
AllowanceForDoubtfulDebts
-155592
CY2022 lgiq Recoveries For Accounts Receivable
RecoveriesForAccountsReceivable
1649632
CY2021 lgiq Recoveries For Accounts Receivable
RecoveriesForAccountsReceivable
3966086
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
155592
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
54619
CY2022 lgiq Accounts Receivable Provision For Bad Debts
AccountsReceivableProvisionForBadDebts
447159
CY2022Q4 us-gaap Fair Value Hedge Assets At Fair Value
FairValueHedgeAssetsAtFairValue
0
CY2022Q4 us-gaap Fair Value Hedge Liabilities At Fair Value
FairValueHedgeLiabilitiesAtFairValue
0
CY2021Q4 us-gaap Fair Value Hedge Assets At Fair Value
FairValueHedgeAssetsAtFairValue
681
CY2021Q4 us-gaap Fair Value Hedge Liabilities At Fair Value
FairValueHedgeLiabilitiesAtFairValue
0
CY2022Q4 lgiq Deposit And Other Receivable
DepositAndOtherReceivable
180000
CY2021Q4 lgiq Deposit And Other Receivable
DepositAndOtherReceivable
400801
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41591
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
403210
CY2022Q4 lgiq Prepayments Deposits And Other Receivables
PrepaymentsDepositsAndOtherReceivables
221591
CY2021Q4 lgiq Prepayments Deposits And Other Receivables
PrepaymentsDepositsAndOtherReceivables
804011
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2169893
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1804131
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2169893
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1804131
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2022 lgiq Certificate Of Amendment Description
CertificateOfAmendmentDescription
Upon the filing of the Certificate of Amendment, and the resulting effectiveness of the Reverse Stock Split, every 13 outstanding shares of the Company’s Common Stock were, without any further action by the Company, or any holder thereof, combined into and automatically became 1 share of the Company’s Common Stock
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022 lgiq Merger Agreement Description
MergerAgreementDescription
As consideration for the Merger, the Company delivered to those persons set forth in the Merger Agreement an aggregate total cash payment of $1,126,000 (the “Cash Consideration”), and an aggregate number of restricted shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), equal to (i) (x) $7,000,000, divided by (ii) the volume weighted average closing price of the Company’s Common Stock for the twenty consecutive trading days prior to Closing (the “Stock Consideration,” and together with the Cash Consideration, the “Merger Consideration”), subject in each case to adjustment as provided in the Merger Agreement. Notwithstanding the foregoing, pursuant to the terms of the Merger Agreement, (i) a portion of the Cash Consideration, in an amount equal to the outstanding balance of that PPP Loan made to Rebel AI in January 2021, shall be withheld at Closing and placed into an escrow account, pending forgiveness or repayment of the PPP Loan, as applicable, and (ii) $2,000,000 of Common Stock shall be withheld from the Stock Consideration and deposited into an escrow account, pending release in accordance with the terms of the Merger Agreement. 
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1126000
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.0001
CY2021Q1 lgiq Issuances Of Common Stock
IssuancesOfCommonStock
100000
CY2021Q1 lgiq Offering Price Per Share
OfferingPricePerShare
5
CY2021Q2 lgiq Agency Agreement Description
AgencyAgreementDescription
Logiq entered into an Agency Agreement (the “Agency Agreement”) with Research Capital Corporation (the “Agent”) relating to the offering (the “Offering”) by the Company of a minimum of 1,666,667 units of securities (each, a “Unit”), and a maximum of 3,333,333 Units, at a price of C$3.00 per Unit (the “Offering Price”), for minimum gross proceeds of C$5,000,000, and maximum gross proceeds of C$10,000,000. Each Unit consists of (i) one share of common stock of the Company, par value $0.0001 per share (and the Common Stock included in a Unit being a “Unit Share”), and (ii) one Common Stock purchase warrant (each, a “Warrant”), where each Warrant entitles the holder thereof to acquire one share of Common Stock (each, a “Warrant Share”) at an exercise price of C$3.50 per Warrant Share, subject to adjustment, at any time before the third anniversary (the “Warrant Expiry Date”) of June 17, 2021 (the “Closing Date”).
CY2022 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
Each Advisory Fee Unit is comprised of (i) one share of Common Stock, and (ii) one warrant exercisable to purchase one share of Common Stock at an exercise price of C$3.50 for a period of 36 months from the Closing Date.
CY2022 lgiq Warrant Description
WarrantDescription
Pursuant to the terms of the Agency Agreement, the Company also agreed to grant the Agent an option (the “Over-Allotment Option”), exercisable in whole or in part, at the sole discretion of the Agent, at any time up to 30 days following the Closing Date, to purchase from the Company: (i) up to such additional number of Units (the “Over-Allotment Units”) equal to 15% of the number of Units sold under the Offering (the “Over-Allotment Number”) at the Offering Price; (ii) up to such number of additional Warrants (the “Over-Allotment Warrants”) equal to 15% of the number of Warrants comprising the Units sold under the Offering at C$0.4898 per Over-Allotment Warrant; (iii) up to such number of additional shares of Common Stock (the “Over-Allotment Unit Shares”) equal to 15% of the number of shares of Common Stock comprising the Units sold under the Offering at C$2.5102 per Over-Allotment Unit Share; or (iv) any combination of Over-Allotment Units, Over-Allotment Warrants, and Over-Allotment Unit Shares, so long as the aggregate number of Over-Allotment Units, Over-Allotment Warrants, and Over-Allotment Unit Shares does not comprise together more than what is included in the Over-Allotment Number of Over-Allotment Units.
CY2022Q1 lgiq Arithmetic Average Purchase Of Shares Percentage
ArithmeticAveragePurchaseOfSharesPercentage
0.97
CY2022Q1 lgiq Warrants To Purchase Of Common Stock
WarrantsToPurchaseOfCommonStock
631579
CY2022Q1 lgiq Common Stock Percentage
CommonStockPercentage
0.015
CY2022Q1 us-gaap Other Commitment
OtherCommitment
40000000
CY2022Q1 lgiq Ownership Limitation Percentage
OwnershipLimitationPercentage
0.0999
CY2022Q1 us-gaap Stock Issued1
StockIssued1
37000000
CY2020Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
35714285
CY2020Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
14284714
CY2020Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.0001
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
564467
CY2020Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 lgiq Total Shares Of Common Stock
TotalSharesOfCommonStock
51762839
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
3550000
CY2019Q4 us-gaap Share Price
SharePrice
0.0001
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
404439
CY2020Q4 us-gaap Share Price
SharePrice
0.0001
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
2788972
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2021Q4 us-gaap Share Price
SharePrice
0.0001
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
132326
CY2022Q4 us-gaap Share Price
SharePrice
0.0001
CY2022 lgiq Vesting Period On Monthly Basis
VestingPeriodOnMonthlyBasis
P5Y
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
250000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.6
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.8
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y8M1D
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
250000
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.6
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
2.8
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
37910393
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49163009
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20126787
CY2022 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
The weighted average number of shares of common stock has been retroactively restated to reflect the 1 for 13 reverse stock-split on February 25, 2020.
CY2021Q3 lgiq Lease Space
LeaseSpace
26954
CY2021Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
26300
CY2021Q4 lgiq Lease Space
LeaseSpace
12422
CY2021Q4 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
17500
CY2022 lgiq Maturity Date
MaturityDate
2022-12-31
CY2020Q1 lgiq Operating Lease Right Of Use And Liabilities
OperatingLeaseRightOfUseAndLiabilities
668000
CY2020Q1 lgiq Operating Lease Lease Payments Present Value Percent
OperatingLeaseLeasePaymentsPresentValuePercent
0.0525
CY2021Q4 lgiq Operating Lease Right Of Use And Liabilities
OperatingLeaseRightOfUseAndLiabilities
206000
CY2021 lgiq Operating Lease Lease Payments Present Value Percent
OperatingLeaseLeasePaymentsPresentValuePercent
0.0325
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3600
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
10000
CY2022 lgiq Operating Lease Rent Expenses Net
OperatingLeaseRentExpensesNet
191772
CY2021 lgiq Operating Lease Rent Expenses Net
OperatingLeaseRentExpensesNet
267000
CY2022Q4 lgiq Lessee Operating Lease Liability Payments Due Future Minimum Sublease Rentals
LesseeOperatingLeaseLiabilityPaymentsDueFutureMinimumSubleaseRentals
210000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021 lgiq Revenues Percentage
RevenuesPercentage
0.10
CY2022 lgiq Revenues Percentage
RevenuesPercentage
0.10
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
25711991
CY2022 lgiq Revenue Remaining Performance Of Obligation Percentage
RevenueRemainingPerformanceOfObligationPercentage
1
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
37346859
CY2021 lgiq Revenue Remaining Performance Of Obligation Percentage
RevenueRemainingPerformanceOfObligationPercentage
1
CY2020 lgiq Revenue Remaining Performance Of Obligation Percentage
RevenueRemainingPerformanceOfObligationPercentage
1

Files In Submission

Name View Source Status
lgiq-20221231_pre.xml Edgar Link unprocessable
lgiq-20221231_cal.xml Edgar Link unprocessable
lgiq-20221231_lab.xml Edgar Link unprocessable
0001575872-23-000678-index-headers.html Edgar Link pending
0001575872-23-000678-index.html Edgar Link pending
0001575872-23-000678.txt Edgar Link pending
0001575872-23-000678-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lg001_ex10-11.htm Edgar Link pending
lg001_ex10-12.htm Edgar Link pending
lg001_ex10-12img01.jpg Edgar Link pending
lg001_ex21-1.htm Edgar Link pending
lg001_ex23-1.htm Edgar Link pending
lg001_ex23-1img01.jpg Edgar Link pending
lg001_ex23-1img02.jpg Edgar Link pending
lg001_ex31-1.htm Edgar Link pending
lg001_ex31-2.htm Edgar Link pending
lg001_ex32-1.htm Edgar Link pending
lg001_ex32-2.htm Edgar Link pending
lg001_img01.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lgiq-20221231.htm Edgar Link pending
lgiq-20221231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
lgiq-20221231_def.xml Edgar Link unprocessable
lgiq-20221231_htm.xml Edgar Link completed
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending